drugset / Trial / NCT01219686
EScitalopram PIndolol ONset of Action
Phase 2/3
Terminated
18 enrolled
Markus KOSEL
H. Lundbeck A/S · collabUniversity Hospital, Basel, Switzerland · collabUniversity Hospital, Geneva · collabUniversity of Lausanne Hospitals · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The main purpose of this study is to determine whether the antidepressant response of escitalopram 30mg/day or escitalopram 20mg/day + pindolol, a beta blocker, is different (faster) compared to a standard dose of escitalopram 20mg/day.
Timeline
- Start
- 2010-10
- Primary completion
- 2013-04
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Escitalopram | Small molecule | 20 mg | Oral |
| Comparator | Escitalopram | Small molecule | 30 mg | Oral |
| Subject | Pindolol | Small molecule | 7.5 mg | Oral |